Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Fineline Cube Apr 12, 2026
Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026
Company Deals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Fineline Cube Oct 31, 2024

China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...

Company

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound

Fineline Cube Oct 31, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...

Company

AstraZeneca China President Leon Wang Involved in Chinese Investigation Amid Industry Probes

Fineline Cube Oct 31, 2024

Leon Wang, Executive Vice President International and AstraZeneca (AZ, NASDAQ: AZN) China President, is cooperating...

Company Drug

AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China

Fineline Cube Oct 31, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...

Company Deals Medical Device

Jiangsu Yuyue Medical Equipment Partners with TÜV SUD to Boost Medical Device Market Access

Fineline Cube Oct 31, 2024

Jiangsu Yuyue Medical Equipment Inc., (SHE: 002223), a Chinese medical equipment manufacturer, has entered into...

Company

GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth

Fineline Cube Oct 31, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

Allmed Medical Products to Establish Wholly Owned Subsidiary in Indonesia

Fineline Cube Oct 31, 2024

China-based Allmed Medical Products Co., Ltd (SHE: 002950) has announced plans to establish a wholly...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Files for New Indication with China’s NMPA

Fineline Cube Oct 31, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that the National Medical Products Administration...

Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for PD-1/VEGF Bispecific Antibody Combination

Fineline Cube Oct 31, 2024

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first patient in a...

Company

AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience

Fineline Cube Oct 31, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...

Company Drug

Shanghai Henlius and Organon Submit Biosimilar Application for Denosumab to FDA

Fineline Cube Oct 31, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) and its US partner Organon (NYSE: OGN) have jointly...

Company

Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion

Fineline Cube Oct 30, 2024

Pfizer Inc. (NYSE: PFE) released its Q3 2024 financial results, reporting revenues of $17.702 billion...

Company Drug

AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV

Fineline Cube Oct 30, 2024

AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from...

Company Medical Device

Acotec Secures NMPA Approval for Acotrace Disposable Catheter Sheath

Fineline Cube Oct 30, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received marketing approval from the...

Company Deals

Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%

Fineline Cube Oct 30, 2024

Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which...

Company Medical Device

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System

Fineline Cube Oct 30, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up...

Company Drug

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients

Fineline Cube Oct 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its drug Scemblix (asciminib) has received accelerated...

Company Deals

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions

Fineline Cube Oct 30, 2024

MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic...

Company Medical Device

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges

Fineline Cube Oct 30, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...

Company

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards

Fineline Cube Oct 30, 2024

On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was...

Posts pagination

1 … 258 259 260 … 648

Recent updates

  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
  • Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
  • Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
  • Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.